WG5 focuses on determining absorbed dose constraints adapted to radiobiological modelling, treatment planning and developing a standardised and harmonised methodology for reporting clinical endpoints to support personalised medicine. WG 5 seeks to identify dose-volume constraints for optimising treatment planning. Based on literature reviews, absorbed dose constraints will be adapted using radiobiological modelling and extrapolated theragnostics data in combination with radiological diagnostic studies for volume determination. Biomarkers predicting acute and late toxicity, early treatment response or describing the tumour aggressiveness will be identified to inform patient stratification, thus refining dose-effect relationships. Further, WG 5 will define and share a standardized dictionary for toxicity reporting analogous to the Common Terminology Criteria for Adverse Events and suggest a standardised format for reporting clinical data needed for developing dose-effect models.
